Skip to main content

Outcomes and risks in palliative pancreatic surgery: an analysis of the German StuDoQ|Pancreas registry

Abstract

Background

Non-resectability is common in patients with pancreatic ductal adenocarcinoma (PDAC) due to local invasion or distant metastases. Then, biliary or gastroenteric bypasses or both are often established despite associated morbidity and mortality. The current study explores outcomes after palliative bypass surgery in patients with non-resectable PDAC.

Methods

From the prospectively maintained German StuDoQ|Pancreas registry, all patients with histopathologically confirmed PDAC who underwent non-resective pancreatic surgery between 2013 and 2018 were retrospectively identified, and the influence of the surgical procedure on morbidity and mortality was analyzed.

Results

Of 389 included patients, 127 (32.6%) underwent explorative surgery only, and a biliary, gastroenteric or double bypass was established in 92 (23.7%), 65 (16.7%) and 105 (27.0%). After exploration only, patients had a significantly shorter stay in the intensive care unit (mean 0.5 days [SD 1.7] vs. 1.9 [3.6], 2.0 [2.8] or 2.1 [2.8]; P < 0.0001) and in the hospital (median 7 days [IQR 4–11] vs. 12 [10–18], 12 [8–19] or 12 [9–17]; P < 0.0001), and complications occurred less frequently (22/127 [17.3%] vs. 37/92 [40.2%], 29/65 [44.6%] or 48/105 [45.7%]; P < 0.0001). In multivariable logistic regression, biliary stents were associated with less major (Clavien–Dindo grade ≥ IIIa) complications (OR 0.49 [95% CI 0.25–0.96], P = 0.037), whereas—compared to exploration only—biliary, gastroenteric, and double bypass were associated with more major complications (OR 3.58 [1.48–8.64], P = 0.005; 3.50 [1.39–8.81], P = 0.008; 4.96 [2.15–11.43], P < 0.001).

Conclusions

In patients with non-resectable PDAC, biliary, gastroenteric or double bypass surgery is associated with relevant morbidity and mortality. Although surgical palliation is indicated if interventional alternatives are inapplicable, or life expectancy is high, less invasive options should be considered.

Peer Review reports

Background

Pancreatic ductal adenocarcinoma (PDAC) is the fourteenth most common malignancy worldwide [1], but will be the second most frequent cause of cancer-related death by 2030 in industrialized countries [2, 3]. Resection is the precondition for cure and should be in combination with systemic treatment the goal in each patient [4, 5]. However, less than 20% of patients with PDAC present in primarily resectable stages [6].

In non-resectable locally advanced or metastatic PDAC, histopathology should be obtained by endoscopic or transcutaneous biopsy, and systemic treatment started as the therapy of choice [4, 5]. Biliary obstruction requires drainage that can be achieved interventionally by endoscopic retrograde cholangiopancreatography (ERCP) with stenting, or percutaneous transhepatic cholangiodrainage (PTCD) and subsequent internalization [7, 8]. Gastroduodenal obstruction should be treated endoscopically only in exceptional cases since stent dislocation and recurrent obstruction are common [4, 5, 9]. For the remaining patients, and after failure of less invasive methods, palliative bypass surgery may be necessary [4, 8, 10,11,12,13].

Metastases or locally advanced disease are discovered during laparotomy or laparoscopy in up to 40% of PDAC patients deemed resectable beforehand [14]. Then, palliative procedures need to be considered. Often, biliary or gastroenteric bypasses or both are established [4, 15, 16].

Only few studies have investigated morbidity and mortality among patients with PDAC after non-resective surgery [17, 18]. Reported morbidity rates range between 28 and 56%, with varying conclusions drawn by the authors [15, 19,20,21]: Some recommend a “watch-and-wait”-strategy instead of prophylactic bypass surgery [20], some conclude that bypass surgery should be avoided in high-risk populations [15], and others favor a selective approach considering the individual patient or the institution’s prerequisites [19, 21, 22]. Considering the morbidity after bypass surgery, and the improvements of endoscopic palliation, the balance of advantages and disadvantages of bypass procedures during laparoscopy or laparotomy is crucial.

Based on the German pancreatic surgery registry StuDoQ|Pancreas, the present study analyzes real-world morbidity and mortality after non-resective surgery in patients with PDAC and identifies associated risk factors.

Methods

StuDoQ|Pancreas registry

Data from the pancreatic surgery registry StuDoQ|Pancreas of the German Society for General and Visceral Surgery (DGAV) were retrospectively analyzed. StuDoQ|Pancreas is a prospectively maintained registry for pancreatic surgery established in September 2013 for the national assessment of quality and risk factors in pancreatic surgery in Germany [23]. At the time assessed by this study, more than 60 institutions were contributing to the registry, and 10 to 20% of all pancreatic surgeries in Germany were registered [24]. Pseudonymized data from the participating centers are prospectively entered using a web-based tool, undergoing automatic plausibility control. Validation by cross-checking with institutional medical data is part of the annual certification process. The informed consent and data safety concept were approved by the Society for Technology, Methods, and Infrastructure for Networked Medical Research (TMF) [23]. The present study was deemed for exemption by the institutional review board of the medical faculty of the LMU University of Munich (20–384 KB).

Data extraction and patients

All patients who provided written informed consent at the specific study site and underwent elective surgery between 2013 and 2018 were assessed for eligibility. Cases with inconsistencies in the dataset or undocumented complication status (Clavien–Dindo grade) were excluded (Fig. 1). All patients with histopathologically confirmed PDAC who underwent non-resective surgery (exploration, biliary bypass, gastroenteric bypass or double [biliary plus gastroenteric] bypass) either scheduled as palliative or when non-resectability turned out upon exploration were included.

Fig. 1
figure 1

Study profile

Data analysis

Beyond the surgical procedure, sex, age, BMI, biliary stent, ASA category, the localization of the tumor, the presence of liver metastases, and preoperative serum markers (bilirubin, CA19-9, and CEA) were obtained. Complications occurring after index surgery during the patient’s stay in the hospital were recorded, and dichotomized according to the Clavien–Dindo classification [25] into minor (grade ≤ II) and major (grade ≥ IIIa). Furthermore, the length of surgery, the length of stay in the intensive care unit (ICU) and in the hospital, the 30-day mortality, the 30-day readmission rate, the recommendation of palliative chemotherapy by the postsurgical multidisciplinary tumor board, and its actual start were recorded.

Statistics

Variables were tested for normality by analyzing histograms and with Shapiro–Wilk tests. Normal distributions were reported in mean and standard deviations and compared using T-tests or ANOVA. Non-normal distributions were reported in median and inter-quartile ranges and compared using Wilcoxon rank-sum tests or Kruskal–Wallis tests. Categorical variables were compared using Fisher’s exact tests or Chi-squared tests. Missing values were not included into testing. When testing multiple times, P-values were adjusted with Hommel correction.

The association between potential risk factors and the occurrence of major complications (Clavien–Dindo grade ≥ IIIa) was explored in univariable logistic regression. Due to the limited number of events in our dataset, data reduction and variable selection were necessary for multivariable logistic regression. Thus, based on prior knowledge and independently from significance-levels in univariable analysis, we included into our full model fit the different types of bypass surgery (exploration vs. biliary/gastroenteric/double bypass), preoperative biliary stenting as a well-known risk factor in pancreatic surgery [26, 27], the presence of liver metastases characterizing more advanced and metastasized disease, and the ASA category to adjust for differences in the general health status of the investigated patients. The influence of having a biliary stent on the risk of complications of different variants of surgery was analyzed in logistic regression with interaction testing.

For regression analyses, missing data were imputed with multivariable imputations by chained equations assuming that they were missing at random using all relevant and available data (age, sex, BMI, biliary stent, ASA category, localization of the tumor, presence of liver metastases, preoperative bilirubin, preoperative CA19-9, preoperative CEA, surgery time, surgical procedure, major complication, postsurgical stay in ICU and in hospital). In 145/389 (37.3%) patients at least one variable was missing (Additional file 1: Fig. S1), therefore imputations were repeated 37 times. Results were checked numerically and visually for plausibility (Additional file 1: Figs. S2–S5). Logistic regression analyses were performed for all imputed datasets individually, and the results pooled.

The statistical analysis was performed using R version 4.2.1 (2022-06-23) [28] within RStudio version 2022.07.1 + 554 (Additional file 1: Table S1). Significance-level was set at 0.05 and all tests were conducted two-sided.

Results

Patients’ characteristics

The current study includes 389 patients with histopathologically confirmed PDAC who underwent palliative, non-resective procedures (Fig. 1). Of these, 127/389 (32.6%) underwent exploration only, 92/389 (23.7%) received a biliary bypass, 65/389 (16.7%) a gastroenteric bypass, and 105/389 (27.0%) the combination of both (double bypass).

The type of surgery depended highly on the localization of the tumor: If the tumor was located in the pancreatic head, biliary bypasses (alone or in combination with a gastroenteric bypass) were more frequently established (183/313, 58.5% vs. 14/76, 18.4%, P < 0.0001). Patients with tumors of the pancreatic body instead, underwent more frequently exploration only or gastroenteric bypass surgery (42/54, 77.8% vs. 150/335, 44.8%, P < 0.0001). In patients with PDAC of the pancreatic tail, exploration only was more common (15/18, 83.3% vs. 112/371, 30.2%, P < 0.0001).

Biliary bypass surgery (alone or in combination with a gastroenteric bypass) was performed more frequently in patients with higher preoperative bilirubin levels (median 3.9 mg/dl [IQR, 0.9 to 11.5] vs. 0.8 [0.4 to 1.9]; P < 0.0001), and in patients who underwent biliary stenting preoperatively (76/114, 66.7% vs. 121/275, 44.0%, P < 0.0001) (see also Biliary stenting). Other baseline parameters were well balanced between the different palliative surgical procedures (Table 1).

Table 1 Patients’ characteristics

Outcomes

The time necessary to perform exploration only was significantly shorter than to establish a gastroenteric, biliary, or double bypass (P < 0.0001, P = 0.002, or P < 0.0001), and gastroenteric bypass surgery took significantly shorter than biliary or double bypass surgery (P < 0.0001, or P < 0.0001). Patients who underwent exploration only had a significantly reduced length of stay in the ICU and in the hospital (both P < 0.0001) (Table 2).

Table 2 Outcomes

Complications occurred in 136/389 (35.0%), and major complications (≥ Clavien–Dindo grade IIIa) in 64/389 (16.5%) patients (Fig. 2a, Table 2). After exploration only, complications in general were less frequent than after biliary, gastroenteric or double bypass surgery (22/127, 17.3% vs. 37/92, 40.2% or 29/65, 44.6% or 48/105, 45.7%; P = 0.0008 or P = 0.0005 or P < 0.0001; Fig. 2b, Table 2). Also, we observed less major complications after exploration only than after biliary or double bypass surgery (9/127, 7.1% vs. 17/92, 18.5% or 25/105, 23.8%; P = 0.047 or P = 0.004, Fig. 2b, Table 2). The rate of major complications after exploration only and after gastroenteric bypass surgery did not differ significantly after adjusting for multiple testing (9/127, 7.1% vs. 13/65, 20.0%; P = 0.059). Also, the occurrence of deadly complications (Clavien–Dindo grade V) differed between the non-resective procedures in general (P = 0.032) but revealed no significant differences between individual groups after adjusting for multiple testing (Table 2).

Fig. 2
figure 2

Rate of complications. Rate and grade of complications according to Clavien–Dindo in general (a) and regarding different types of non-resective surgery (b)

In multivariable logistic regression adjusting for preoperatively placed biliary stents, ASA category, and liver metastases, establishing a biliary (OR 3.58 [95% CI 1.48 to 8.64], P = 0.005), gastroenteric (OR 3.50 [1.39 to 8.81], P = 0.008), or double bypass (OR 4.96 [2.15 to 11.43], P < 0.001) was associated with more major complications than exploration only.

Postoperative chemotherapy

The postsurgical multidisciplinary tumor board recommended palliative chemotherapy in 328/389 (84.3%) patients, and in 123/328 (37.5%) it was actually administered. Patients started chemotherapy after sole exploration as frequently as after biliary, gastroenteric or double bypass surgery (P = 0.731) (Table 2). The rate of patients receiving palliative chemotherapy was significantly reduced in patients, who experienced any postoperative complication compared to those who did not (29/53, 54.7% vs. 94/120, 78.3%; P = 0.003).

Biliary stenting

Patients with preoperatively placed biliary stents had higher bilirubin levels than patients without (median 2.2 mg/dl [IQR 0.9 to 5.4] vs. 1.0 [0.5 to 10.5]; P = 0.017), and biliary bypasses were more often established (76/114, 66.7% vs. 121/275, 44.0%; P < 0.0001). Preoperative biliary stenting was associated with a reduced risk of major complications in multivariable analysis (OR 0.49 [95% CI 0.25 to 0.96], P = 0.037; Fig. 3). The presence or absence of a biliary stent did not influence the risk of major complications associated with bypass surgery in interaction testing (P = 0.981).

Fig. 3
figure 3

Risk of major complication. Predictors of major complications (Clavien–Dindo grade ≥ IIIa). Results were derived from univariable, and multivariable logistic regression based of the imputed dataset including all 389 patients. The reference category is marked by an asterisk (*). ASA ASA physical status classification system, BMI body mass index, CA19-9 tumor marker carbohydrate antigen 19-9, CEA tumor marker carcinoembryonic antigen, CI confidence interval, IQR interquartile range, OR odds ratio

Subgroup of patients with normal bilirubin-levels

In the subgroup of 177 patients with normal bilirubin levels (≤ 1.1 mg/dl), complications in general were less frequent after exploration only than after biliary, gastroenteric or double bypass surgery (13/81, 16.0% vs. 12/29, 41.4% or 16/38, 42.1% or 14/29, 48.3%; P = 0.036 or P = 0.015 or P = 0.006). Also, we observed less major complications after exploration only than after biliary, gastroenteric, or double bypass surgery, however, the difference was only significant for the latter (7/81, 8.6% vs. 4/29, 13.8% or 6/38, 15.8% or 10/29, 34.5%; P = 0.952 or P = 0.714 or P = 0.013).

Liver metastases

In the current dataset, bypass surgery (instead of exploration only) was performed regardless of whether liver metastases were present or not (92/140, 65.7% vs. 142/204, 69.6%; P = 0.481). Patients with liver metastases had major complications as frequently as patients without liver metastases (21/140, 15.0% vs. 34/204, 16.7%; P = 0.765), and the 30-day mortality rate was comparable (9/140, 6.4% vs. 6/204, 2.9%; P = 0.177).

Discussion

The present study analyzed the real-world outcome after exploration and bypass procedures in non-resectable PDAC. The morbidity and mortality rates we found were remarkably high, consistent with previous findings [15,16,17,18,19,20,21, 29]. In particular, bypass surgery took longer than exploration alone, patients stayed longer in the intensive care unit and in the hospital, and complications were more frequent and more severe. This is in agreement with previous studies reporting lower morbidity after exploration only instead of bypass surgery (e.g., Bartlett et al. 12% vs. 20% or Williamsson et al. 31% vs. 67%) [15, 19,20,21]. Comparable to the trend in our study, an Italian registry study described mortality rates between 7.8% and 14.4% after bypass surgery, compared to 5.2% after explorative laparotomy and 2.6% after explorative laparoscopy [17].

The current study underlines that explorative surgery is associated with relevant complications, and the morbidity further increases when bypass surgery is performed. Our data did not yield baseline parameters identifying a specific high-risk subpopulation except the ASA category. Thus, the indication for a surgical bypass continues to be based on clinical judgement.

Biliary obstruction occurs in 70–80% of patients with non-resectable pancreatic cancer someday [30]. Guidelines recommend palliation by endoscopic retrograde cholangiopancreaticograpy (ERCP) or percutaneous transhepatic cholangiodrainage (PTCD) with subsequent internalization instead of planned biliary bypass surgery due to reduced morbidity [4, 5, 8]. With advances such as the development of metal stents, disadvantages of endoscopic techniques such as the recurrence of biliary obstruction were reduced. After failure of ERCP, endoscopic ultrasound-guided biliary drainage (as choledochoduodenostomy or hepaticogastrostomy) can be discussed alternatively to PTCD. In non-resectable situations during explorative surgery however, the establishment of a biliary bypass may be considered [8]. High life expectancy (increasing the risk of stent obstruction and reintervention), low comorbidities, a high individual risk of biliary obstruction, or a history of stent dysfunction can indicate a biliary bypass [8, 12, 13], but should be balanced against the increased morbidity and mortality compared to exploration only (Fig. 4).

Fig. 4
figure 4

Recommended treatment algorithm. Recommended treatment algorithm of patients with pancreatic ductal adenocarcinoma. Rhombuses symbolize decisions, radiused rectangles symbolize interventions. Elements within the red box represent decisions or interventions during surgery. Grey boxes highlight different areas of concern such as obtaining histopathology, gastroduodenal obstruction, and biliary obstruction

Of note, in our study the presence of a biliary stent was associated with reduced post-surgical morbidity, consistently with findings from Lyons et al. [21] and Spanheimer et al. [19]. The presence or absence of a biliary stent did not influence the risk of major complications associated with bypass surgery in interaction analysis. Still, in resective pancreatic surgery preoperative biliary stenting is associated with increased morbidity [26, 27]. Considering this, and in the light of the current study, the establishment of a prophylactic biliary bypass must be discussed carefully in patients with normal bilirubin-levels, and appears questionable in patients with functional, preoperatively placed biliary stent [31]. A recent study of Vreeland et al. supports this, showing that obstructive symptoms occurred frequently after exploration only, but could generally be treated without surgery [32].

Duodenal obstruction occurs in 6–25% of patients with non-resectable pancreatic cancer at some time [33, 34]. Endoscopic palliation by stenting is associated with shorter hospitalization times, early clinical improvement, and less morbidity than surgical gastrojejunostomy. However, stent dislocations and recurrent obstructions are common, and food tolerance is lower than after gastroenterostomy in the long term [9, 35]. Therefore, in patients with symptomatic duodenal obstruction, endoscopic palliation by stenting or percutaneous endoscopic gastrostomy (PEG) tube placement should be reserved to exceptions [4, 5, 9]. In patients with existing or impending duodenal obstruction, a life expectancy of 3 months or longer [9], and acceptable comorbidities, a gastroenteric bypass is indicated [4, 10, 11] and may also be established in non-resectable situations upon ongoing explorative surgery (Fig. 4). At tertiary centers with high endoscopic expertise and in selected patients, endoscopic ultrasound-guided gastroenterostomy can alternatively be discussed [36].

As morbidity and mortality of single (gastroenteric or biliary) and double (gastroenteric and biliary) bypass were comparable in our and prior studies [10, 11, 15, 34], one could argue, as soon as either a biliary bypass or a gastroenteric bypass is needed, a double bypass should be established. We still believe that the indication of each bypass should be reviewed individually as described earlier: First, endoscopic palliation of biliary obstruction is effective, and gastroduodenal obstruction requiring palliation less frequent. Second, although differences were not significant, in the gastroenteric and double bypass group deadly complications and 30-day mortality were most common, and in multivariable regression the risk of major complications highest. This might be consequence of both, a (often more advanced) tumor causing gastroduodenal obstruction, malnutrition and a reduced general health status, as well as the more invasive surgery in the double bypass group. Third, long-term outcomes from other studies support a “watch-and-wait” strategy: Espat et al. found that 151/155 (97.4%) patients with non-resectable PDAC at exploration did not require bypass surgery prior to death [37]. Lyons et al. report that 72/157 (46%) patients with non-resectable PDAC upon exploration required an additional invasive procedure in their further course of disease, independently whether a bypass was established or not [21]. Spanheimer et al. and Williamsson et al. report comparable rates of readmission or reinterventions [19, 20]. In summary, in these studies bypass surgery did not reduce the need of (endoscopic or surgical) reinterventions.

Patients with resectable and borderline resectable tumors should undergo surgery aiming for resection. Despite modern diagnostic staging, small metastases often remain undetected until explorative surgery [38]. Also, especially in the era of neoadjuvant chemotherapy, the predictive value of the image-based evaluation of local resectability is limited [39]. In patients with radiologically occult metastatic disease, diagnostic laparoscopy can reduce the surgical trauma. Sell et al. found, that these patients started palliative chemotherapy more quickly, and their overall survival was improved compared to patients undergoing exploratory laparotomy [40]. Still, the optimal definition of the subpopulation of patients benefiting from diagnostic laparoscopy remains controversial [41,42,43].

However, and in concordance with the current study, any reduction of the surgical trauma might improve the outcomes of patients with non-resectable PDAC. Thus, diagnostic laparoscopy in patients with high risk of metastatic disease, reservation of palliation to symptomatic patients, and preference of minimally invasive methods when appropriate, could in combination reduce procedural morbidity, increase the rate of patients receiving palliative chemotherapy, and accelerate its start. Future studies should explore the optimal combination, sequencing, and timing of diagnostic and therapeutic measures to maximize our patients’ cumulative quality of life [31, 44].

Admittedly, this study has limitations due to its design and the underlying registry. The registry does not specify whether non-resectability was known prior to surgery or turned out upon exploration. Patients undergoing explorative laparotomy in curative intention might be otherwise healthier than patients requiring planned bypass surgery. Pencovich et al. for instance describe a 30-day mortality of 16.6% in patients who underwent bypass surgery in purely palliative intention [22]. However, in the current study also in the subgroup of patients with preoperatively normal bilirubin-levels—suggesting that biliary bypass surgery was conducted prophylactically upon intraoperative detection of non-resectability—the morbidity was significantly increased after bypass surgery and comparable to the whole study population. Future studies should compare the outcomes of exploration only and bypass surgery in the subgroup of patients with tumors deemed resectable beforehand. Also, some potentially interesting data were often not available (e.g., survival beyond 30 days, postoperative quality of life, postoperative interventions, and reoperation due to biliary or duodenal obstruction) and could therefore not be analyzed. Still, the current study quantifies the real-world morbidity and mortality associated with bypass surgery in patients with non-resectable PDAC. This can help to properly balance the risks and benefits of palliative pancreatic surgery against those of less invasive alternatives.

Conclusion

Having no reasonable option of resection during exploration will continue to play a role in pancreatic surgery. In this situation, the establishment of a biliary or gastroenteric bypass is associated with a relevant risk of complications. Thus, bypass surgery is indicated if less invasive alternatives are inapplicable or life expectancy is high, however, it should be up to careful clinical judgement in experienced pancreatic centers considering less invasive options.

Availability of data and materials

The data that support the findings of this study are part of the StuDoQ|Pancreas registry and were provided by the German Society for General and Visceral Surgery (DGAV). Thus, they are not publicly available. Access can be requested from the German Society for General and Visceral Surgery (DGAV, http://www.dgav.de/studoq.html).

Abbreviations

ASA:

ASA physical status classification system

BMI:

Body mass index

CA19-9:

Tumor marker carbohydrate antigen 19-9

CEA:

Tumor marker carcinoembryonic antigen

CI:

Confidence interval

ERCP:

Endoscopic retrograde cholangiopancreaticograpy

ICU:

Intensive care unit

IQR:

Interquartile range

OR:

Odds ratio

PEG:

Percutaneous endoscopic gastrostomy

PDAC:

Pancreatic ductal adenocarcinoma

PTCD:

Percutaneous transhepatic cholangiodrainage

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  PubMed  Google Scholar 

  2. Quante AS, Ming C, Rottmann M, Engel J, Boeck S, Heinemann V, et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030. Cancer Med. 2016;5(9):2649–56.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.

    Article  CAS  PubMed  Google Scholar 

  4. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Behrman SW, Benson AB, et al. Pancreatic Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology: National Comprehensive Cancer Network NCCN; 2020. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed 26 Nov 2019.

  5. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v56-68.

    Article  PubMed  Google Scholar 

  6. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363(9414):1049–57.

    Article  CAS  PubMed  Google Scholar 

  7. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(8):1028–61.

    Article  PubMed  Google Scholar 

  8. Stark A, Hines OJ. Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42(1):163–76.

    Article  PubMed  Google Scholar 

  9. Jeurnink SM, Steyerberg EW, van Hooft JE, van Eijck CH, Schwartz MP, Vleggaar FP, et al. Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc. 2010;71(3):490–9.

    Article  PubMed  Google Scholar 

  10. Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK, Coleman J, et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg. 1999;230(3):322–8; discussion 8-30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Van Heek NT, De Castro SM, van Eijck CH, van Geenen RC, Hesselink EJ, Breslau PJ, et al. The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg. 2003;238(6):894–902; discussion 5.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Glazer ES, Hornbrook MC, Krouse RS. A meta-analysis of randomized trials: immediate stent placement vs surgical bypass in the palliative management of malignant biliary obstruction. J Pain Symptom Manage. 2014;47(2):307–14.

    Article  PubMed  Google Scholar 

  13. Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev. 2006;2: CD004200.

    Google Scholar 

  14. Allen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev. 2016;7: CD009323.

    PubMed  Google Scholar 

  15. Bartlett EK, Wachtel H, Fraker DL, Vollmer CM, Drebin JA, Kelz RR, et al. Surgical palliation for pancreatic malignancy: practice patterns and predictors of morbidity and mortality. J Gastrointest Surg. 2014;18(7):1292–8.

    Article  PubMed  Google Scholar 

  16. Shah MM, Ajay PS, Meltzer RS, Jajja MR, Gullickson CR, Cardona K, et al. The aborted whipple: why, and what happens next? J Surg Oncol. 2022;125(4):642–5.

    Article  PubMed  Google Scholar 

  17. Balzano G, Capretti G, Callea G, Cantu E, Carle F, Pezzilli R. Overuse of surgery in patients with pancreatic cancer. A nationwide analysis in Italy. HPB (Oxford). 2016;18(5):470–8.

    Article  Google Scholar 

  18. van der Geest LGM, Lemmens V, de Hingh I, van Laarhoven C, Bollen TL, Nio CY, et al. Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. Br J Surg. 2017;104(11):1568–77.

    Article  PubMed  Google Scholar 

  19. Spanheimer PM, Cyr AR, Liao J, Johlin FC, Hoshi H, Howe JR, et al. Complications and survival associated with operative procedures in patients with unresectable pancreatic head adenocarcinoma. J Surg Oncol. 2014;109(7):697–701.

    Article  PubMed  Google Scholar 

  20. Williamsson C, Wennerblom J, Tingstedt B, Jonsson C. A wait-and-see strategy with subsequent self-expanding metal stent on demand is superior to prophylactic bypass surgery for unresectable periampullary cancer. HPB (Oxford). 2016;18(1):107–12.

    Article  Google Scholar 

  21. Lyons JM, Karkar A, Correa-Gallego CC, D’Angelica MI, DeMatteo RP, Fong Y, et al. Operative procedures for unresectable pancreatic cancer: does operative bypass decrease requirements for postoperative procedures and in-hospital days? HPB (Oxford). 2012;14(7):469–75.

    Article  Google Scholar 

  22. Pencovich N, Orbach L, Lessing Y, Elazar A, Barnes S, Berman P, et al. Palliative bypass surgery for patients with advanced pancreatic adenocarcinoma: experience from a tertiary center. World J Surg Oncol. 2020;18(1):63.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Wellner UF, Keck T. Quality indicators in pancreatic surgery: lessons learned from the German DGAV StuDoQ|Pancreas registry. Visc Med. 2017;33(2):126–30.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Wellner UF, Klinger C, Lehmann K, Buhr H, Neugebauer E, Keck T. The pancreatic surgery registry (StuDoQ|Pancreas) of the German Society for General and Visceral Surgery (DGAV)—presentation and systematic quality evaluation. Trials. 2017;18(1):163.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.

    Article  PubMed  Google Scholar 

  26. Bolm L, Petrova E, Woehrmann L, Werner J, Uhl W, Nuessler N, et al. The impact of preoperative biliary stenting in pancreatic cancer: a case-matched study from the German nationwide pancreatic surgery registry (DGAV StuDoQ|Pancreas). Pancreatology. 2019;19(7):985–93.

    Article  PubMed  Google Scholar 

  27. Scheufele F, Schorn S, Demir IE, Sargut M, Tieftrunk E, Calavrezos L, et al. Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head: a meta-analysis of current literature. Surgery. 2017;161(4):939–50.

    Article  PubMed  Google Scholar 

  28. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016.

  29. Kneuertz PJ, Cunningham SC, Cameron JL, Torrez S, Tapazoglou N, Herman JM, et al. Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience. J Gastrointest Surg. 2011;15(11):1917–27.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Maire F, Hammel P, Ponsot P, Aubert A, O’Toole D, Hentic O, et al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. Am J Gastroenterol. 2006;101(4):735–42.

    Article  PubMed  Google Scholar 

  31. Stackhouse KA, Storino A, Watkins AA, Gooding W, Callery MP, Kent TS, et al. Biliary palliation for unresectable pancreatic adenocarcinoma: surgical bypass or self-expanding metal stent? HPB (Oxford). 2020;22(4):563–9.

    Article  Google Scholar 

  32. Vreeland TJ, Bohan PMK, Newhook TE, Allen CJ, Prakash LR, Maxwell JE, et al. Contemporary assessment of need for palliative bypass after aborted pancreatoduodenectomy following neoadjuvant therapy. J Gastrointest Surg. 2022;26(2):352–9.

    Article  PubMed  Google Scholar 

  33. House MG, Choti MA. Palliative therapy for pancreatic/biliary cancer. Surg Clin North Am. 2005;85(2):359–71.

    Article  PubMed  Google Scholar 

  34. Gurusamy KS, Kumar S, Davidson BR. Prophylactic gastrojejunostomy for unresectable periampullary carcinoma. Cochrane Database Syst Rev. 2013;2: CD008533.

    Google Scholar 

  35. Ly J, O’Grady G, Mittal A, Plank L, Windsor JA. A systematic review of methods to palliate malignant gastric outlet obstruction. Surg Endosc. 2010;24(2):290–7.

    Article  PubMed  Google Scholar 

  36. Baron TH. EUS gastroenterostomy: why do bad things happen to good procedures? Gastrointest Endosc. 2022;95(1):90–1.

    Article  PubMed  Google Scholar 

  37. Espat NJ, Brennan MF, Conlon KC. Patients with laparoscopically staged unresectable pancreatic adenocarcinoma do not require subsequent surgical biliary or gastric bypass. J Am Coll Surg. 1999;188(6):649–55; discussion 55-7.

    Article  CAS  PubMed  Google Scholar 

  38. Glant JA, Waters JA, House MG, Zyromski NJ, Nakeeb A, Pitt HA, et al. Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery. 2011;150(4):607–16.

    Article  PubMed  Google Scholar 

  39. Zins M, Matos C, Cassinotto C. Pancreatic adenocarcinoma staging in the era of preoperative chemotherapy and radiation therapy. Radiology. 2018;287(2):374–90.

    Article  PubMed  Google Scholar 

  40. Sell NM, Fong ZV, Del Castillo CF, Qadan M, Warshaw AL, Chang D, et al. Staging laparoscopy not only saves patients an incision, but may also help them live longer. Ann Surg Oncol. 2018;25(4):1009–16.

    Article  PubMed  Google Scholar 

  41. De Rosa A, Cameron IC, Gomez D. Indications for staging laparoscopy in pancreatic cancer. HPB (Oxford). 2016;18(1):13–20.

    Article  Google Scholar 

  42. Paracha M, Van Orden K, Patts G, Tseng J, McAneny D, Sachs T. Opportunity lost? Diagnostic laparoscopy in patients with pancreatic cancer in the national surgical quality improvement program database. World J Surg. 2019;43(3):937–43.

    Article  PubMed  Google Scholar 

  43. Takadate T, Morikawa T, Ishida M, Aoki S, Hata T, Iseki M, et al. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Surg Today. 2021;51(5):686–94.

    Article  PubMed  Google Scholar 

  44. Perinel J, Adham M. Palliative therapy in pancreatic cancer-palliative surgery. Transl Gastroenterol Hepatol. 2019;4:28.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work has been conducted using the StuDoQ|Pancreas registry provided by the Study, Documentation and Quality Center (Studien-, Dokumentations- und Qualitätszentrum, StuDoQ) of the German Society for General Surgery (Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie, DGAV) with the ID 2018-0006. We thank the patients who agreed to be registered in the German DGAV StuDoQ|Pancreas Registry and the nurses and doctors involved in their treatment and enrollment. Also, we would like to thank staff of the DGAV for the maintenance of the registry, the data extraction, and their help regarding its analysis.

Funding

Open Access funding enabled and organized by Projekt DEAL. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

Authors

Contributions

FOH, RCM, JGD and JW are responsible for study conception and design. TK, MA, HW, NCN, CR, JK, MG, DKB, WH, MKA, JGD, and JW performed the operations and collected the data. FOH, RCM, JGD and JW analyzed and interpreted the data. FOH and RCM drafted the manuscript. FOH, RCM, MW, TK, MA, HW, NCN, CR, JK, MG, DKB, WH, MKA, JGD, and JW revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jens Werner.

Ethics declarations

Ethics approval and consent to participate

All patients provided written informed consent prior inclusion into the registry. The informed consent and data safety concept were approved by the Society for Technology, Methods, and Infrastructure for Networked Medical Research (TMF). The present study was deemed for exemption by the institutional review board of the medical faculty of the LMU University of Munich (Ethikkommission der Medizinischen Fakultät der LMU München, Pettenkoferstrasse 8, 80336 München; 20-384 KB). All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

FOH has received a research leave grant from the Bavarian Centre for Cancer Research (BZKF), partner site Munich, Germany. MW has received funding from the German Research Foundation (DFG, Grant #401299842). The remaining authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Software. Fig S1. Missingness and Missingness Patterns. Fig S2. Box-and-whisker plots of imputed values. Fig S3. Density plot of imputed values. Fig S4. Strip plot of imputed values. Fig S5. Mean and standard deviation of imputed values.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hofmann, F.O., Miksch, R.C., Weniger, M. et al. Outcomes and risks in palliative pancreatic surgery: an analysis of the German StuDoQ|Pancreas registry. BMC Surg 22, 389 (2022). https://doi.org/10.1186/s12893-022-01833-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12893-022-01833-3

Keywords

  • Pancreatic ductal adenocarcinoma
  • Explorative surgery
  • Palliative surgery
  • Biliary bypass
  • Gastroenteric bypass
  • Registry analysis